Pharmaceuticals in Thoughts from the Centre

Intelligent biopharma: Forging the links across the value chain

By Mark Steedman, PhD, Manager, Centre for Health Solutions

Deloitte-uk-intelligent-biopharma

This week, we have launched the first in a series of reports on artificial intelligence (AI) and its potential impact in driving the digital transformation of biopharma. This overview report, Intelligent biopharma: Forging the links across the value chain, explores the challenges and opportunities in AI adoption and the potential ways that AI might impact the different segments of the biopharma value chain (see Figure 1).1

Continue reading

Posted on 04/10/2019 | 0 Comments

So, just how attractive are Biosimilars for pharma companies?

By Peter Wallace, Partner in Consulting

Deloitte-uk-biosimilars-for-pharma-companies

Last week’s blog discussed the cost effectiveness of biosimilars and the extent to which they offer value for money for healthcare systems.1 This week’s blog, by Peter Wallace, our lead Partner for digital transformation of Life Sciences and Healthcare, looks at the issue through the lens of the pharma company.

Continue reading

Posted on 20/09/2019 | 0 Comments

The cost-effectiveness of biosimilars: Delivering value for money from pharma spending

By Karen Taylor and Pratik Avhad, Centre for Health Solutions

Deloitte-uk-cost-effectiveness-of-biosimilars

Two months ago, I participated in a Westminster Health Forum panel discussing Biologics and Biosimilars. My remit was to discuss the cost effectiveness of biosimilars and their contribution to value for money in pharma spending. This week’s blog shares the findings from the research we did for the presentation.

Continue reading

Posted on 13/09/2019 | 0 Comments

The journey of my internship: Titanic or Apollo 11?

By Nahiyan Khan, Intern, Monitor Deloitte

Satellite

My journey as an intern started back in December 2018, alone with my laptop and wavering confidence, fuelled by the daunting stories from my peers about the hundreds of internships they had applied to and the succession of rejections they seemed to get like some sort of corporate ‘tinder’. This, coupled with my third year dissertation constantly on my mind, meant that I didn’t have the most motivated mind set. Still, I remember deciding to apply to one last internship before retiring for the day - Monitor Deloitte. This choice came from a mixture of wanting to get an insight into what strategy consulting actually does, and hearing about Deloitte as a great place for a new graduate to start their career. First would come the immersive online assessment, followed by the job simulation and then, if successful, the final assessment (see Figure 1).

Continue reading

Posted on 30/08/2019 | 0 Comments

Forging a new path to commercialization for cell and gene therapies

By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP

Deloitte-uk-green-trees-and-grass

This week’s blog, by Greg Reh from the US firm, first appeared on the US Center for Health Solutions blog site. The blog features Greg’s commentary on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.

Continue reading

Posted on 16/08/2019 | 0 Comments

Why improving inclusion and diversity in clinical trials should be a research priority

By Karen Taylor, Director, Centre for Health Solutions

Diversity

Several weeks ago I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit sufficient trial participants from important demographic groups, especially women, racial and ethnic minorities, and the elderly. As a result, the outcomes seen in clinical trials are likely to be unrepresentative of the patient outcomes in the real world.

Continue reading

Posted on 08/08/2019 | 0 Comments

Deal breaker? Mitigating cyber risk in life sciences M&A

By Nadeem Mohammed, Deloitte MCS Limited

Lock

Imagine the scene: it’s Friday night, eight senior executives at one of the world’s largest companies are sitting around a private dining table at a swanky city restaurant. They’re there to celebrate the closure of a transaction they’ve been toiling over for the past 12 months. You’re the Deal Lead, and you’ve just taken a congratulatory phone call from the Chief Executive – the Board are delighted with the acquisition, which will now be at the heart of the company’s growth strategy. You’ve given blood, sweat and tears on this – you raise a glass towards the table and take a quiet moment to reflect on what is surely a career defining moment.

Continue reading

Posted on 26/07/2019 | 0 Comments

Safety first: Technology and analytics could help transform pharmacovigilance

By Kelly Traverso, Life Sciences R&D, Deloitte Consulting LLP

Safety

This week's blog, by Kelly Traverso from the US firm, first appeared on the US Center for Health Solutions blog site. The blog looks at how utilising automation can help transform pharmacovigilance.

Continue reading

Posted on 12/07/2019 | 0 Comments

2019 Human Capital Trends: Reinvent with a human focus – the implications for the Life Sciences industry

By Shivani Maitra, Partner, Consulting

Hctrends

This time of year is always a highlight for me as it sees the publication of our annual Global Human Capital Trends report, based on the views of 10,000 survey respondents across 119 countries. This year’s findings reinforce the views of colleagues in the Life Sciences (LS) team, specifically that LS organisations need to rethink the workforce experience, adapt to a more diverse workforce and transform their approach to leadership development.

Continue reading

Posted on 28/06/2019 | 0 Comments

How biopharma R&D can thrive in the UK: Insights from an expert panel discussion

By Matthew Thaxter, Analyst, Centre for Health Solutions

Pharma

Following the launch of our ninth annual report ‘Unlocking R&D productivity: Measuring the return from pharmaceutical innovation 2018’, we hosted a panel discussion in London to explore how innovation in the wider R&D ecosystem can unlock R&D productivity. Our panel of experts comprising representatives from big pharma, a small innovative biotech company, the ABPI and the Medicines Discovery Catapult discussed a wide range of topics including: the UK healthcare ecosystem, government policies in the UK aimed at supporting the life sciences industry, the evolving skills and talent agenda and the role of regulators in encouraging innovation. Below are some of the key highlights from the discussion.

Continue reading

Posted on 21/06/2019 | 0 Comments